An analysis of the evolutionary dynamics of cancer cells with KRAS mutations in patients with colorectal cancer after treatment demonstrated that these mutations had been present before the initiation of EGFR blockade, in rare subclones harboring approximately thousands of cancer cells [6]. This evidence concerns the gene EGFR and cancer.